Pinebridge Investments L.P. purchased a new position in Eli Lilly And Co (NYSE:LLY) during the second quarter, HoldingsChannel reports. The fund purchased 103,080 shares of the company’s stock, valued at approximately $11,420,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of LLY. Bessemer Group Inc. raised its holdings in shares of Eli Lilly And Co by 2,354.5% during the 2nd quarter. Bessemer Group Inc. now owns 569,510 shares of the company’s stock worth $63,096,000 after acquiring an additional 546,307 shares in the last quarter. Cedar Capital LLC raised its holdings in shares of Eli Lilly And Co by 17.5% during the 2nd quarter. Cedar Capital LLC now owns 2,459 shares of the company’s stock worth $272,000 after acquiring an additional 367 shares in the last quarter. Thoroughbred Financial Services LLC raised its holdings in shares of Eli Lilly And Co by 1.4% during the 1st quarter. Thoroughbred Financial Services LLC now owns 7,612 shares of the company’s stock worth $988,000 after acquiring an additional 105 shares in the last quarter. Advisor Group Inc. raised its holdings in shares of Eli Lilly And Co by 0.9% during the 1st quarter. Advisor Group Inc. now owns 66,256 shares of the company’s stock worth $8,601,000 after acquiring an additional 567 shares in the last quarter. Finally, Naples Global Advisors LLC raised its holdings in shares of Eli Lilly And Co by 1.1% during the 2nd quarter. Naples Global Advisors LLC now owns 15,591 shares of the company’s stock worth $1,727,000 after acquiring an additional 170 shares in the last quarter. 76.78% of the stock is currently owned by institutional investors.

In other news, SVP Stephen F. Fry sold 9,452 shares of the stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $115.00, for a total transaction of $1,086,980.00. Following the transaction, the senior vice president now owns 100,211 shares of the company’s stock, valued at approximately $11,524,265. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Alfonso G. Zulueta sold 19,500 shares of the stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $112.91, for a total value of $2,201,745.00. Following the transaction, the senior vice president now directly owns 38,306 shares in the company, valued at approximately $4,325,130.46. The disclosure for this sale can be found here. 0.11% of the stock is currently owned by corporate insiders.

Shares of LLY traded down $0.63 during midday trading on Friday, reaching $110.84. 131,504 shares of the stock were exchanged, compared to its average volume of 3,204,832. Eli Lilly And Co has a 52 week low of $104.17 and a 52 week high of $132.13. The company has a current ratio of 1.13, a quick ratio of 0.87 and a debt-to-equity ratio of 4.98. The company’s 50 day moving average is $111.51 and its two-hundred day moving average is $116.94. The company has a market capitalization of $107.26 billion, a P/E ratio of 19.95, a PEG ratio of 1.96 and a beta of 0.16.

Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings results on Tuesday, July 30th. The company reported $1.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.45 by $0.05. Eli Lilly And Co had a return on equity of 70.86% and a net margin of 33.76%. The business had revenue of $5.64 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same quarter in the prior year, the company earned $1.48 EPS. The business’s revenue was up .9% compared to the same quarter last year. On average, sell-side analysts expect that Eli Lilly And Co will post 5.73 EPS for the current year.

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th were given a dividend of $0.645 per share. This represents a $2.58 dividend on an annualized basis and a dividend yield of 2.33%. The ex-dividend date was Wednesday, August 14th. Eli Lilly And Co’s payout ratio is 46.49%.

LLY has been the topic of several recent research reports. Zacks Investment Research lowered Eli Lilly And Co from a “buy” rating to a “hold” rating in a report on Tuesday, May 21st. ValuEngine lowered Eli Lilly And Co from a “buy” rating to a “hold” rating in a report on Friday, June 28th. Bank of America set a $120.00 price target on Eli Lilly And Co and gave the company a “neutral” rating in a report on Tuesday. Finally, Goldman Sachs Group initiated coverage on Eli Lilly And Co in a report on Tuesday, May 28th. They set a “buy” rating and a $135.00 price target on the stock. Nine equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $122.93.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Recommended Story: Short Selling

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.